All In MedTech

Device Trial Radar · NCT04546438

Patient Satisfaction and Safety of Miradry Treatment for Axillary Hyperhidrosis

Patient Quality of Life and Safety of Treatment With Microwave Technology for Axillary Hyperhidrosis

Last checked: Nov 20, 2026Latest source record: Dec 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

100

Actual

Start

Sep 4, 2020

Primary completion

Dec 1, 2023

Study completion Dec 1, 2023

Sponsor

Lead sponsor
Region ÖstergötlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 14, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary localized hyperhidrosis is a dermatological disorder that involves excessive sweat production without an underlying cause. The disease usually affects the axillae but can also involve palms, soles of the feet or face and causes major problems in many social situations with a negative impact on quality of life and mental health. In this study, the investigators want to investigate the effect of microwave therapy (MiraDry®) on self-rated sweating, quality of life and anxiety in participants with severe axillary hyperhidrosis. The study also aims to evaluate the safety (side effects) of the method and long term effects over 1 year of follow upp.

Conditions

  • Axillary Hyperhidrosis

Interventions

  • miraDry®Device

    MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands. In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The effectiveness of miraDry treatmentTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vrinnevisjukhuset

    Norrköping, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.